NASDAQ, TSX: NVCN
VANCOUVER, July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or
the "Company") (NASDAQ, TSX: NVCN) announced today that, in
connection with its new final short form base shelf prospectus (the
"Base Shelf Prospectus") filed with securities regulatory
authorities in the provinces of British
Columbia, Alberta,
Saskatchewan, Manitoba and Ontario (the "Provinces") and its
corresponding shelf registration statement on Form F-10 (the
"Registration Statement") with the U.S. Securities and Exchange
Commission (the "SEC") under the U.S./Canada Multijurisdictional
Disclosure System, which were filed to replace its prior expiring
base shelf prospectus and related registration statement, the
Company has filed a prospectus supplement (the "Prospectus
Supplement") with the securities regulatory authorities in the
Provinces and with the SEC covering the issuance, from time to
time, of units, warrants and common shares of the Company
underlying the outstanding warrants previously issued pursuant to
the Company's underwritten public offering of 6,609,588 Series A
units of the Company and 19,066,780 Series B units of the Company
at a price of $1.46 per unit, which
closed on November 17, 2017. This
"administrative" filing effectively moves the registration of these
underlying units, warrants and common shares from the Company's
prior registration statement, which expired on July 9, 2018, to the new Registration Statement.
It does not involve a new financing.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such
jurisdiction.
A copy of the Registration Statement, including the related
prospectus, or the Prospectus Supplement may be obtained by
submitting a request to Chris Clark,
Chief Financial Officer, at Neovasc's address at 5138-13562
Maycrest Way, Richmond, British
Columbia, Canada, V6V 2J7. Copies of the Base Shelf
Prospectus and Prospectus Supplement are available on SEDAR at
www.sedar.com. Copies of the Registration Statement can be found on
the SEC website at www.sec.gov.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc
ReducerTM (the "Reducer"), for the treatment of
refractory angina, which is not currently commercially available in
the United States and has been
commercially available in Europe
since 2015, and the TiaraTM (the "Tiara"), for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the
United States, Canada and
Europe.
View original
content:http://www.prnewswire.com/news-releases/neovasc-announces-filing-of-administrative-prospectus-supplement-relating-to-expiry-of-prior-shelf-prospectus--registration-statement-300680996.html
SOURCE Neovasc Inc.